ERCC1表达与食管癌铂类化疗疗效及预后的相关性研究

丁晓权

（榆林市第一医院胸心外科，陕西 榆林，719000）

浏览次数：124次 下载次数：441次

摘要：

目的 探讨ERCC1表达（切除修复交叉互补组1）与食管癌铂类化疗疗效及预后的相关性。方法 选择2014年2月至 2016年2月我院收治的食管癌患者160例，根据患者ERCC1表达情况分为阴性表达组（85例）和阳性表达组（75例）。给予所有患者含铂类化疗方案进行治疗，并检测ERCC1表达情况。比较两组患者化疗疗效及预后情况。结果 阴性组与阳性组化疗疗效相比，无明显差异（P>0.05）；阴性表达组患者生存期明显长于阳性表达组（P<0.05）。结论 ERCC1表达与食管癌铂类化疗疗效无明显相关性，但阳性表达提示患者预后较差，生存期短。

关键词：ERCC1；食管癌；铂类化疗；预后

中图分类号：R735.2 文献标志码：A文章编号：2096-1413(2017)11-0024-02

Correlation study between expression of ERCC1 and effect and prognosis in the treatment of platinum-based chemotherapy in esophagus cancer
DING Xiao-quan
(Department of Thoracic and Cardiovascular Surgery, the First Hospital of Yulin，Yulin 719000, China)

ABSTRACT: Objective To discuss the dependency of ERCC1 expression and platinum based chemotherapy in esophagus cancer. Methods From February 2014 to February 2016, 160 cases of esophagus cancer patients in our hospital were selected, according to the expression of ERCC1, all the patients were divided into the negative expression group (85 cases) and positive expression group (75 cases). All the patients were given the scheme of containing platinum chemotherapy for treatment, and the expression of ERCC1 was detected. The chemotherapeutic effect and conditions in prognosis of the two groups were compared. Results There was no significant difference in the efficacy of chemotherapy between thetwo groups (P>0.05). The lifetime of the negative expression group was significantly longer than that of the positive expression group (P <0.05). Conclusion There is no obviously correlation of the ERCC1 expression and platinum based chemotherapy for esophagus cancer, but the positive expression reminds poor prognosis and shorter lifetime.
KEYWORDS: ERCC1; esophagus cancer; platinum based chemotherapy; prognosis

参考文献：
[1] 张虹,顾康生.ERCC1蛋白的表达与晚期食管癌含顺铂方案化疗疗效的临床观察[J].中国临床药理学与治疗学,2015,20(5):546-551.
[2] 姚艺玮,何义富,季楚舒,等.ERCC1基因检测指导晚期食管癌个体化治疗的临床研究[J].安徽医科大学学报,2015,50(5):640-644.
[3] 王维民,周炎,金俊,等.ERCC1、TS在胃癌组织中的表达与术后辅助化疗预后的关系[J].现代中西医结合杂志,2015,24(30):3307-3310.

[4] 高雯雯,谭洁,吴锦昌,等.联合铂类的化疗方案在晚期食管癌中的临床评价及Pol(I)对铂类化疗药物敏感性的影响.肿瘤学杂志,2015,21(2):151-156.
[5] 郭学云,姚艺玮,胡冰.外周血ERCC1-C8092A基因型指导晚期食管癌个体化治疗的初步探讨[J].安徽医学,2015,36(1):30-33.
[6] 冯征,祖超,周勇安.根据ERCC1、RRM1及TUBB3检测结果对食管鳞癌患者实行个体化辅助治疗的随机对照研究[J].现代肿瘤医学,2014,22(4):813-815.
[7] 宁召锋,李梁,刘霞,等.DNA聚合酶β表达对食管癌放疗敏感性及预后的影响[J].肿瘤学杂志,2016,22(4):305-309.
[8] 马冬,杨冬阳,罗少燕,等.COX-2和ERCC1在胃癌中的表达及其临床意义[J].实用医学杂志,2014,30(16):2585-2587.
[9] 王澜,李晓旭,韩春,等.食管癌长期生存患者临床特征及治疗相关因素分析[J].中华放射肿瘤学杂志,2016,25(6):565-570.